AB0976 Efficacy of intra-articular injection of prp- drived growth factor (PRP WITHOUT PLATELET AND WBC) versus hyaluronic acid on pain and function of patients with knee osteoarthritis: a single-blinded randomised clinical trial

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 1611
• Main Authors: Raeissadat, S.A., gharooee ahangar, A., Rayegani, S.M.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2018
• Subjects: Acids; Arthritis; Clinical trials; Growth factors; Hyaluronic acid; Injection; Knee; Osteoarthritis; Pain; Platelets; Quality of life; Rheumatic diseases
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-eular.3701

BackgroundKnee osteoarthritis is the most common joint disease.ObjectivesWe aimed to compare the efficacy and safety of intra-articular injection of PRP-drived growth factor versus hyaluronic acid (HA) on pain and function of patients with knee osteoarthritis.MethodsIn this single-blinded randomised clinical trial, patients with symptomatic osteoarthritis of knee were assigned to receive 2 intra-articular injections of PRP-drived growth factor in 3  weeks or 3 weekly injections of HA. Our primary outcome was the mean change from baseline until 2 and 6  months post intervention in scores of visual analogue scale, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index.ResultsA total of 69 patients entered final analysis. The mean age of patients was 58.2 ± 7.41  years and 81.2% were women. Total WOMAC index decreased from 42.9 ± 13.51 to 26.8 ± 13.45 and 24.4 ± 16.54 at 2 and 6  months in the PRGF group (within subjects p = 0.001), and from 38.8 ± 12.62 to 27.8 ± 11.01 and 27.4 ± 11.38 at 2 and 6  months in the HA group (within subjects p = 0.001), respectively (between subjects p = 0.631). There was no significant difference between PRP-drived growth factor and HA groups in patients’ satisfaction and minor complications of injection, whereas patients in HA group reported significantly lower injection-induced pain.Abstract AB0976 – Table 1WOMAC scoresVAS PainFunctionStiffnessTotal PRGFBaseline9.2±2.9730.6±10.093.0±2.0142.9±13.517.8±1.78At 2 month5.8±2.9619.5±9.791.6±1.6626.8±13.454.9±2.21At 6 month5.3±3.6017.6±11.701.5±1.8424.4±16.544.6±2.78P value within groups0.00010.00010.00010.00010.0001HyalganBaseline8.7±3.0127.8±9.622.3±1.6438.8±12.627.4±1.48At 2 month5.9±2.6520.6±8.041.2±1.3927.8±11.014.8±1.80At 6 month5.9±2.7920.1±7.771.3±1.4827.4±11.384.8±2.39P value within groups0.00010.00010.00010.00010.0001P value Between Groups0.8470.8940.1890.9850.648Abstract AB0976 – Figure 1ConclusionsIn 6 months follow up, PRP-drived growth factor and HA, both are effective options to decrease pain and improvement of function in patients with mild to moderate knee osteoarthritis.References[1] Raeissadat, SA, Babaee, M, Rayegani, SM. An overview of platelet products (PRP, PRGF, PRF, etc.) in the Iranian studies [published onlineahead of print July 28, 2017]. Futur Sci OA. doi:10.4155/fsoa-2017-0045.[2] Raeissadat, SA, Rayegani, SM, Babaee, M, Ghorbani, E. The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis. Pain Res Treat. 2013;2013:165967. Google Scholar[3] Raeissadat, SA, Rayegani, SM, Hassanabadi, H. Knee osteoarthritis injection choices: platelet-rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1–8.[4] Raeissadat SA, Rayegani SM, Moridnia M, Dehgolan SR. Intra articular ozone or hyaluronic acid injection: which one is superior in patients with knee osteoarthritis? a 6-month randomized clinical trial.Annals of the Rheumatic Diseases2017;76(Suppl 2):1547–1548.Disclosure of InterestNone declared